Definium Therapeutics, Inc. DFTX R2KR3KPHARMA
Company Overview
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +261.08% |
| 6 Months: | +54.77% |
| 3 Months: | -16.61% |
| 1 Month: | -4.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)49.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 25.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DFTX Definium Therapeutics, Inc. R2KR3KPHARMA | 36.00 | -10.50 | $4.84B | 0.00% | -44.54% | -64.09% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.16M | 40.90M | 45.67M | 47.58M | 59.22M | - |
| Operating Income | -13.85M | -45.22M | -17.23M | -18.50M | -16.94M | -16.98M | -20.86M | -29.18M | -21.62M | -22.20M | -24.46M | -24.79M | - | -32.16M | -40.90M | -45.67M | -47.58M | -59.22M | -75.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.75M | -40.41M | -65.99M | -49.17M | -75.85M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 602.00K | 2.34M | 1.27M | 1.27M | 1.25M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -13.76M | -45.25M | -17.20M | -18.45M | -16.96M | -16.48M | -24.82M | -29.13M | -17.92M | -54.40M | -5.85M | -13.68M | - | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M | -158.99M |
| Diluted EPS | - | -0.11 | -0.61 | -0.66 | -0.60 | -0.56 | -0.65 | -0.76 | -0.45 | -1.14 | -0.26 | -0.27 | -0.41 | -0.35 | -0.50 | -0.78 | - | -0.71 | -1.44 |
| R&D Expense | 6.81M | 8.07M | 9.02M | 10.24M | 9.33M | 7.77M | 12.60M | 14.78M | 13.20M | 11.71M | 14.64M | 17.19M | - | 23.36M | 29.81M | 30.98M | - | 41.48M | 48.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 66.33M | 93.87M | 103.92M | 166.31M |
| Operating Income | -33.03M | - | -66.33M | -93.87M | -103.92M | -166.31M |
| EBITDA | - | - | -63.15M | -91.65M | -105.87M | -178.31M |
| Interest Expense | - | 359.00K | - | 920.00K | 2.28M | 5.48M |
| Pretax Income | - | - | -56.80M | -95.73M | -108.68M | -183.79M |
| Tax Provision | - | -1.16M | 0 | - | - | - |
| Net Income | -33.94M | - | -56.80M | -95.73M | -108.68M | -183.79M |
| Diluted EPS | - | - | -1.84 | -2.44 | -1.54 | -2.06 |
| R&D Expense | 18.63M | 34.79M | 36.17M | 52.12M | 65.30M | 117.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 81.52M | 164.00M | 169.99M | 124.54M | 302.15M | 440.10M |
| Total Equity | 0 | 4.78M | 75.87M | 151.66M | 150.92M | 78.13M | 241.45M | 332.33M |
| Cash & Equivalents | - | - | 80.09M | 133.54M | 142.14M | 99.70M | 273.74M | 257.84M |
| Long Term Debt | - | - | - | - | - | 14.13M | 21.85M | 40.58M |
| Total Liabilities | - | - | 5.65M | 12.34M | 19.08M | 46.41M | 60.70M | 107.77M |
| Current Liabilities | - | - | 3.01M | 10.41M | 17.89M | 32.25M | 38.85M | 66.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.60M | -45.82M | -50.14M | -64.36M | -79.13M | -131.56M |
| Investing Cash Flow | - | -297.00K | - | - | 0 | -151.61M |
| Financing Cash Flow | 96.70M | 98.82M | 59.05M | 21.85M | 253.20M | 267.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -44.7% | - | -37.6% | -122.5% | -45.0% | -55.3% |
| ROCE % | -42.1% | - | -43.6% | -101.7% | -39.5% | -44.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.36% | 11.23M | $414.49M |
| 2 | Avoro Capital Advisors LLC | 5.35% | 7.19M | $265.27M |
| 3 | Driehaus Capital Management, LLC | 5.09% | 6.85M | $252.59M |
| 4 | Jupiter Topco LLC | 4.18% | 5.62M | $207.22M |
| 5 | Capital World Investors | 3.99% | 5.37M | $198.07M |
| 6 | FMR, LLC | 3.54% | 4.75M | $175.38M |
| 7 | Price (T.Rowe) Associates Inc | 3.46% | 4.65M | $171.66M |
| 8 | Geode Capital Management, LLC | 2.71% | 3.64M | $134.49M |
| 9 | State Street Corporation | 2.28% | 3.07M | $113.11M |
| 10 | Capital International Investors | 2.21% | 2.96M | $109.35M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DFTX
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQdXVKMTBaaEVVeG83bXFYNGNrLXV0REpqcS1hMDRFd0lhNHdFb3F0RjNEY2tpT01RclZhX01tUTE4M3VsSWYtRDF4Y0kxVXZGSFVjLThQWTRPZUdfd2RUbnRiWmIwSnpQeVh5by03V21nZE1yVmJsSWhKc2xRSXduYXM5Ny1zbVFIVXVlX1…
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxOay00RC1DbXpDVk5HX2JpSVVmNEVpalhoRmwzY19ZSFMxcHJ3amd1eHo3WXBwdnNlQ0l0WGFLOXRYYThSbnJQb2ZHR2lJV1B2ZGxxekZuWkJkZE5JWkhldmFmTkRnSHRLejM4eGpBeU5OcHdxVC1OSXVpTDN4MF9QYUJvRlBpWVVJN19lc1…
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress - Moomoo
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUERJRzlCZV8zeGVMYjFsdTJwVVhIVlIyeFVJUjVHM3hyNy1ESnJmdkM0S1J6YkdmU1laNnhEaFNmUUN4Nm5JMVVtaTZPMnJuOVhpcGNseEJmaEd1ck1LY3FSZklkU25YV19NcW1IUkRKWENkZmpZSGt0R3lsa051YjJIeVdqYk1ZTkJ4Um…
Definium Therapeutics (DFTX) Stock Climbed, So What Is Behind The Fresh Attention? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQVEpXQl9LcVloc0xOTkk4eWhDYTlmY0V3aFhOS1dfMDFpaFlfcVdxeUdrMWYzeGQxWDk5dFZZN3pnR0R5NzBDUC1PX0VwR1VIYnZOZ185QTV4cWFJU0xnNG12MlVINGJncjhiTnFiaTF3d3g4NzZqWTdtRWZIcHRCTC10ZTY2VmVhcGczQ0…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE8yQWpPU0VVQW5VdG1RWXRvbFl5bGstTXlVSmc4TUt0MlBsbS16c3Axd3h6akdjaDA5VE5YWTVOUWx4TkxrQVYwZklPbTAxSHlq?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data - TradingView
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNOElEQURQSU9LZXJZYVhPbWdoZXRLZWRfTndtWTFrS1ExRnZtN0lLOE0tWUJQbkhKZWJmZHVLRExESjdQYmNPRHBhMmRkWUdBY3hKWU52MWpRLVBjWG9Xc2EwQTVaQ1huNEF2dWhGQlB6SzV2aFg3R1h0NmtCM3l0Mm5aaVp6V3NiT1pwUT…
DFTX — Frequently Asked Questions
What is the current share price of Definium Therapeutics, Inc. (DFTX)?
As of 2026-10-22 16:30 PDT, Definium Therapeutics, Inc. (DFTX) trades at $36.00 on NasdaqGS. Its 52-week range is $8.88 to $48.45.
What is the market capitalisation of DFTX?
Definium Therapeutics, Inc. (DFTX) has a market capitalisation of $4.84B on NasdaqGS.
What is the P/E ratio of DFTX?
DFTX trades at a trailing price-to-earnings (P/E) ratio of -10.50. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 5.40.
What is the return on equity (ROE) of DFTX?
DFTX has a return on equity (ROE) of -64.09%. Its return on capital employed (ROCE) is -44.54%.
Is DFTX a good stock to buy?
This page provides a data-driven analysis of Definium Therapeutics, Inc. (DFTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.